| Íàèìåíîâàíèå | Ïðîèçâîäèòåëü | Öåíà $ | Öåíà ðóá
|
|---|
| ÑÀÁ ÑÈÌÏËÅÊÑ ÑÓÑÏ.Ä/ÂÍÓÒÐ.ÏÐÈÌ. 69,19ÌÃ/ÌË 30ÌË ¹1 (PFIZER, ÔÐÀÍÖÈß) | PFIZER | | 165.61
|
| ÑÀÁÅËÜÍÈÊ ÊÐÅÌ Ä/ÒÅËÀ 75ÌË (ÔÎÐÀ-ÔÀÐÌ/ÊÎÐÎËÅÂ ÔÀÐÌ, ÐÎÑÑÈß) | ÔÎÐÀ-ÔÀÐÌ/ÊÎÐÎËÅÂ ÔÀÐÌ | | 52.93
|
| ÑÀÁÅËÜÍÈÊ-ÝÂÀËÀÐ ÊÐÅÌ 100ÌË (ÝÂÀËÀÐ, ÐÎÑÑÈß) | ÝÂÀËÀÐ | | 56.63
|
| ÑÀÁÅËÜÍÈÊ-ÝÂÀËÀÐ Í-ÊÀ 50ÌË (ÝÂÀËÀÐ, ÐÎÑÑÈß) | ÝÂÀËÀÐ | | 45.6
|
| ÑÀÁÅËÜÍÈÊ-ÝÂÀËÀÐ ÒÀÁ. 500ÌÃ ¹60 (ÝÂÀËÀÐ, ÐÎÑÑÈß) | ÝÂÀËÀÐ | | 64.81
|
| ÑÀÁÅËÜÍÈÊ-ÝÂÀËÀÐ ×ÀÉ 50à (ÝÂÀËÀÐ, ÐÎÑÑÈß) | ÝÂÀËÀÐ | | 24.33
|
| ÑÀËÀÌÎË ÝÊÎ ÀÝÐÎÇÎËÜ 100ÌÊÃ/ÄÎÇÀ 200ÄÎÇ ¹1 (IVAX-CR/NORTON, ÈÐËÀÍÄÈß) | IVAX-CR/NORTON | | 103.07
|
| ÑÀËÈÍ ÑÏÐÅÉ ÍÀÇ. 30ÌË ¹1 (SAGMEL INÑ, ÑØÀ) | SAGMEL INÑ | | 106.32
|
| ÑÀËÈÍ ÑÏÐÅÉ ÍÀÇ. 30ÌË ¹1 (SAGMEL INÑ/INSTITUTO DE ANGELI, ÈÒÀËÈß) | SAGMEL INÑ/INSTITUTO DE ANGELI | | 98.5
|
| ÑÀËÈÖÈËÎÂÀß ÊÈÑËÎÒÀ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ.ÑÏÈÐÒ. 1% 40ÌË ¹1 (ÉÎÄÍÛÅ ÒÅÕÍÎËÎÃÈÈ È ÌÀÐÊÅÒÈÍÃ, ÐÎÑÑÈß) | ÉÎÄÍÛÅ ÒÅÕÍÎËÎÃÈÈ È ÌÀÐÊÅÒÈÍÃ | | 10.19
|
| ÑÀËÈÖÈËÎÂÀß ÊÈÑËÎÒÀ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ.ÑÏÈÐÒ. 2% 40ÌË ¹1 (ÉÎÄÍÛÅ ÒÅÕÍÎËÎÃÈÈ È ÌÀÐÊÅÒÈÍÃ, ÐÎÑÑÈß) | ÉÎÄÍÛÅ ÒÅÕÍÎËÎÃÈÈ È ÌÀÐÊÅÒÈÍÃ | | 10.69
|
| ÑÀËÎÔÀËÜÊ ÑÓÏÏ. ÐÅÊÒÀËÜÍÛÅ 500ÌÃ ¹10 (DR. FALK PHARMA, ÃÅÐÌÀÍÈß) | DR. FALK PHARMA | | 606.84
|
| ÑÀËÎÔÀËÜÊ ÒÀÁ. 250ÌÃ ¹50 (DR. FALK PHARMA, ÃÅÐÌÀÍÈß) | DR. FALK PHARMA | | 757.65
|
| ÑÀËÎÔÀËÜÊ ÒÀÁ. 500ÌÃ ¹50 (DR. FALK PHARMA, ÃÅÐÌÀÍÈß) | DR. FALK PHARMA | | 1280.24
|
| ÑÀËÔÅÒÊÀ ÀÍÒÈÑÅÏÒÈ×ÅÑÊÀß ÑÏÈÐÒÎÂÀß 135ÌÌX185ÌÌ ¹1 (Ì.Ê. ÀÑÅÏÒÈÊÀ, ÐÎÑÑÈß) | Ì.Ê. ÀÑÅÏÒÈÊÀ | | 1.73
|
| ÑÀËÔÅÒÊÀ ÀÍÒÈÑÅÏÒÈ×ÅÑÊÀß ÑÏÈÐÒÎÂÀß Ä/ÈÍ 30ÌÌ Õ 60ÌÌ ¹1 (Ì.Ê. ÀÑÅÏÒÈÊÀ, ÐÎÑÑÈß) | Ì.Ê. ÀÑÅÏÒÈÊÀ | | 0.41
|
| ÑÀËÔÅÒÊÀ ÀÍÒÈÑÅÏÒÈ×ÅÑÊÀß ÑÏÈÐÒÎÂÀß Ä/ÈÍ ¹1 6Õ10ÑÌ ¹1 (Ì.Ê. ÀÑÅÏÒÈÊÀ, ÐÎÑÑÈß) | Ì.Ê. ÀÑÅÏÒÈÊÀ | | 0.74
|
| ÑÀËÔÅÒÊÈ JAMAICA ÎÄÍÎÑË. Ñ ÐÈÑÓÍÊÎÌ ¹50 (ÁÓÌÔÀ ÃÐÓÏÏ, ÐÎÑÑÈß) | ÁÓÌÔÀ ÃÐÓÏÏ | | 13.29
|
| ÑÀËÔÅÒÊÈ PREMIAL ÂË. Ä/ÄÅÒÑÊ. ÃÈÃ. Ñ ÀËÎÅ-ÂÅÐÀ ¹20 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ | | 20.42
|
| ÑÀËÔÅÒÊÈ PREMIAL ÂËÀÆ. ÀÍÒÈÁÀÊÒÅÐ Ä/ØÊÎËÜÍÈÊÎÂ ¹15 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ | | 14.29
|
| ÑÀËÔÅÒÊÈ PREMIAL ÂËÀÆÍÛÅ ÀÍÒÈÁÀÊÒÅÐÈÀËÜÍÛÅ ¹15 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ | | 13.57
|
| ÑÀËÔÅÒÊÈ PREMIAL ÂËÀÆÍÛÅ Ä/ÈÍÒÈÌ.ÃÈÃÈÅÍÛ Ñ ÌÎËÎ×.ÊÈÑËÎÒÎÉ ¹20 (ÁÓÌÔÀ ÃÐÓÏÏ, ÐÎÑÑÈß) | ÁÓÌÔÀ ÃÐÓÏÏ | | 21.12
|
| ÑÀËÔÅÒÊÈ PREMIAL ÂËÀÆÍÛÅ Î×ÈÙ.(4 ÀÐÎÌÀÒÀ) ¹15 ÀÊÖÈß "ÏËÀÒÎ×ÅÊ Â ÏÎÄÀÐÎÊ" (ÁÓÌÔÀ ÃÐÓÏÏ, ÐÎÑÑÈß) | ÁÓÌÔÀ ÃÐÓÏÏ | | 13.69
|
| ÑÀËÔÅÒÊÈ PREMIAL Ä/ÄÅÒÑÊ ÃÈÃ. Î×ÈÙ.ÊÐÅÌÎÂÛÅ ¹10 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ | | 17.43
|
| ÑÀËÔÅÒÊÈ PREMIAL Ä/ÄÅÒÑÊ ÃÈÃ. Î×ÈÙ.ÊÐÅÌÎÂÛÅ ¹20 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ | | 30.88
|
| ÑÀËÔÅÒÊÈ PREMIAL Ä/ÄÅÒÑÊÎÉ ÃÈÃÈÅÍÛ ÍÅÀÐÎÌÀÒÈÇ. ¹40 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ | | 35.45
|
| ÑÀËÔÅÒÊÈ PREMIAL Ä/ÄÅÒÑÊÎÉ ÃÈÃÈÅÍÛ Ñ ÀËÎÅ-ÂÅÐÀ ¹10 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ | | 13.17
|
| ÑÀËÔÅÒÊÈ PREMIAL Ä/ÄÅÒÑÊÎÉ ÃÈÃÈÅÍÛ Ñ ÀËÎÅ-ÂÅÐÀ ¹80 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ | | 66.66
|
| ÑÀËÔÅÒÊÈ PREMIAL Ä/ÈÍÒÈÌÍÎÉ ÃÈÃÈÅÍÛ ÆÅÍ. ¹10 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ | | 13.17
|
| ÑÀËÔÅÒÊÈ PREMIAL Ä/ÈÍÒÈÌÍÎÉ ÃÈÃÈÅÍÛ ÆÅÍ. ¹20 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ | | 21.6
|
| ÑÀËÔÅÒÊÈ PREMIAL Ä/ÑÍßÒÈß ÌÀÊÈßÆÀ ¹20 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ | | 20.39
|
| ÑÀËÔÅÒÊÈ ÌÀÐËÅÂÛÅ ÑÒÅÐ. 16Õ14 ¹10 (ÄÂÓÕÑËÎÉÍÛÅ) (ÌÅÄÊÎÌÏÐÅÑÑ ÏËÞÑ, ÐÎÑÑÈß) | ÌÅÄÊÎÌÏÐÅÑÑ ÏËÞÑ | | 7.77
|
| ÑÀËÔÅÒÊÈ ÌÀÐËÅÂÛÅ ÑÒÅÐ. 16Õ14 ¹20 (ÄÂÓÕÑËÎÉÍÛÅ) (ÌÅÄÊÎÌÏÐÅÑÑ ÏËÞÑ, ÐÎÑÑÈß) | ÌÅÄÊÎÌÏÐÅÑÑ ÏËÞÑ | | 13.4
|
| ÑÀËÔÅÒÊÈ ÌÀÐËÅÂÛÅ ÑÒÅÐ. 45Õ29 ¹5 (ÄÂÓÕÑËÎÉÍÛÅ) (ÌÅÄÊÎÌÏÐÅÑÑ ÏËÞÑ, ÐÎÑÑÈß) | ÌÅÄÊÎÌÏÐÅÑÑ ÏËÞÑ | | 17.07
|
| ÑÀËÔÅÒÊÈ ÌÀÐËÅÂÛÅ ÑÒÅÐ. 45Õ29 ¹5 (ÄÂÓÕÑËÎÉÍÛÅ) (ÍÀÂÒÅÊÑ, ÐÎÑÑÈß) | ÍÀÂÒÅÊÑ | | 15.21
|
| ÑÀËÜÁÓÒÀÌÎË ÀÝÐÎÇÎËÜ 12ÌË 200ÄÎÇ ¹1 (ÀËÒÀÉÂÈÒÀÌÈÍÛ ÇÀÎ, ÐÎÑÑÈß) | ÀËÒÀÉÂÈÒÀÌÈÍÛ ÇÀÎ | | 50.74
|
| ÑÀËÜÁÓÒÀÌÎË ÀÝÐÎÇÎËÜ 12ÌË ¹1 (ÌÎÑÕÈÌÔÀÐÌÏÐÅÏÀÐÀÒÛ, ÐÎÑÑÈß) | ÌÎÑÕÈÌÔÀÐÌÏÐÅÏÀÐÀÒÛ | | 73.2
|
| ÑÀËÜÃÈÌ Ð-Ð Ä/ÈÍÃ. 1ÌÃ/ÌË 10ÌË ¹10 (ÏÓËÜÌÎÌÅÄ, ÐÎÑÑÈß) | ÏÓËÜÌÎÌÅÄ | | 217.04
|
| ÑÀËÜÒÎÑ ÒÀÁ. 7,23ÌÃ ¹30 (ÏÓËÜÌÎÌÅÄ, ÐÎÑÑÈß) | ÏÓËÜÌÎÌÅÄ | | 180.16
|
| ÑÀÍÂÀË ÒÀÁ. Ï/Î 10ÌÃ ¹10 (LEK D.D., ÑËÎÂÅÍÈß) | LEK D.D. | | 168.61
|
| ÑÀÍÂÀË ÒÀÁ. Ï/Î 10ÌÃ ¹20 (LEK, ÑËÎÂÅÍÈß) | LEK | | 231.37
|
| ÑÀÍÃÂÈÐÈÒÐÈÍ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ.ÑÏÈÐÒ. 0,2% 50ÌË ¹1 (ÂÈËÀÐ, ÐÎÑÑÈß) | ÂÈËÀÐ | | 57.63
|
| ÑÀÍÄÎÑÒÀÒÈÍ Ð-Ð Ä/ÈÍ. 0,05ÌÃ/ÌË 1ÌË ¹5 (NOVARTIS PHARMA, ØÂÅÉÖÀÐÈß) | NOVARTIS PHARMA | | 1355.97
|
| ÑÀÍÄÐÀ ÒÀÁ. ÃÎÌÅÎÏ. 250ÌÃ ¹30 (ÂÈËÀÐ, ÐÎÑÑÈß) | ÂÈËÀÐ | | 61.67
|
| ÑÀÍÎÐÈÍ ÊÀÏËÈ ÍÀÇ. 0,05% 10ÌË ¹1 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 40.86
|
| ÑÀÍÎÐÈÍ ÊÀÏËÈ ÍÀÇ. 0,1% 10ÌË ¹1 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 49.61
|
| ÑÀÍÎÐÈÍ Ñ ÌÀÑËÎÌ ÝÂÊÀËÈÏÒÀ ÝÌÓËÜÑÈß 0,1% 10ÌË ¹1 ÔË. (IVAX PHARMACEUTICALS, ×ÅÕÈß) | IVAX PHARMACEUTICALS | | 52.61
|
| ÑÀÍÎÐÈÍ ÑÏÐÅÉ ÍÀÇ. 0,1% 10ÌË ¹1 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 78.48
|
| ÑÀÐÈÄÎÍ ÒÀÁ. ¹10 (BAYER SANTE FAMILIALE, ÔÐÀÍÖÈß) | BAYER SANTE FAMILIALE | | 104.97
|
| ÑÅÀËÅÊÑ ÔÎÐÒÅ ÊÀÏÑ. 400ÌÃ ¹12 (ÂÈÑ ÎÎÎ, ÐÎÑÑÈß) | ÂÈÑ ÎÎÎ | | 696.14
|
| ÑÅÀËÅÊÑ ÔÎÐÒÅ ÊÀÏÑ. 400ÌÃ ¹12 (ÃÍÖ ÏÌ ÔÀÐÌÀ, ÐÎÑÑÈß) | ÃÍÖ ÏÌ ÔÀÐÌÀ | | 933.06
|
| ÑÅÁÈÄÈÍ ÒÀÁ. ¹20 (GLAXO SMITH KLINE, ÏÎËÜØÀ) | GLAXO SMITH KLINE | | 56.39
|
| ÑÅÁÎÇÎË ØÀÌÏÓÍÜ ÎÒ ÏÅÐÕÎÒÈ 100ÌË (ÄÈÎÍÈÑ ÎÎÎ, ÐÎÑÑÈß) | ÄÈÎÍÈÑ ÎÎÎ | | 195.81
|
| ÑÅÁÎÇÎË ØÀÌÏÓÍÜ ÎÒ ÏÅÐÕÎÒÈ 5ÌË ¹5 (ÄÈÎÍÈÑ ÎÎÎ, ÐÎÑÑÈß) | ÄÈÎÍÈÑ ÎÎÎ | | 77.31
|
| ÑÅÄÀË-Ì ÒÀÁ. ¹10 (MILVE PHARMACEUTICALS JSC, ÁÎËÃÀÐÈß) | MILVE PHARMACEUTICALS JSC | | 42.05
|
| ÑÅÄÀË-Ì ÒÀÁ. ¹20 (MILVE PHARMACEUTICALS JSC, ÁÎËÃÀÐÈß) | MILVE PHARMACEUTICALS JSC | | 84.2
|
| ÑÅÄÀËÈÒ ÒÀÁ. 300ÌÃ ¹50 (ÔÀÐÌÑÒÀÍÄÀÐÒ-ËÅÊÑÐÅÄÑÒÂÀ, ÐÎÑÑÈß) | ÔÀÐÌÑÒÀÍÄÀÐÒ-ËÅÊÑÐÅÄÑÒÂÀ | | 77.19
|
| ÑÅÄÀËÜÃÈÍ-ÍÅÎ ÒÀÁ. ¹10 (BALKANPHARMA, ÁÎËÃÀÐÈß) | BALKANPHARMA | | 61.99
|
| ÑÅËÅÍÀÇÀ Ð-Ð Ä/ÈÍ. 50ÌÊÃ/ÌË 10ÌË ¹10 (VASSERBURGER ARTZNEIMITTELVERK DR. MADAUS, ÃÅÐÌÀÍÈß) | VASSERBURGER ARTZNEIMITTELVERK DR. MADAUS | | 3013.5
|
| ÑÅËÌÅÂÈÒ ÒÀÁ. Ï/Î ¹30 (ÓÔÀÂÈÒÀ, ÐÎÑÑÈß) | ÓÔÀÂÈÒÀ | | 89.91
|
| ÑÅËÌÅÂÈÒ ÒÀÁ. Ï/Î ¹60 (ÓÔÀÂÈÒÀ, ÐÎÑÑÈß) | ÓÔÀÂÈÒÀ | | 122.06
|
| ÑÅËÌÅÂÈÒ ÒÀÁ. Ï/Î ¹60 (ÔÀÐÌÑÒÀÍÄÀÐÒ-ÓÔÀÂÈÒÀ, ÐÎÑÑÈß) | ÔÀÐÌÑÒÀÍÄÀÐÒ-ÓÔÀÂÈÒÀ | | 126.87
|
| ÑÅÌÀÊÑ ÊÀÏËÈ 0,1% 3ÌË ¹1 (ÏÅÏÒÎÃÅÍ, ÐÎÑÑÈß) | ÏÅÏÒÎÃÅÍ | | 318.43
|
| ÑÅÌÀÊÑ ÊÀÏËÈ 1% 3ÌË ¹1 (ÏÅÏÒÎÃÅÍ, ÐÎÑÑÈß) | ÏÅÏÒÎÃÅÍ | | 1645.2
|
| ÑÅÍÀÄÅ ÒÀÁ. ¹500 (CIPLA, ÈÍÄÈß) | CIPLA | | 511.61
|
| ÑÅÍÍÛ ËÈÑÒÜß 1,5à ¹20 Ô/ÏÀÊ. (ÈÂÀÍ-×ÀÉ ÇÀÎ, ÐÎÑÑÈß) | ÈÂÀÍ-×ÀÉ ÇÀÎ | | 24.41
|
| ÑÅÍÍÛ ËÈÑÒÜß 1,5Ã ¹20 Ô/ÏÀÊ. (ÊÐÀÑÍÎÃÎÐÑÊËÅÊÑÐÅÄÑÒÂÀ ÎÀÎ, ÐÎÑÑÈß) | ÊÐÀÑÍÎÃÎÐÑÊËÅÊÑÐÅÄÑÒÂÀ ÎÀÎ | | 34.44
|
| ÑÅÍÍÛ ËÈÑÒÜß 1,5Ã ¹20 Ô/ÏÀÊ. (ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ, ÐÎÑÑÈß) | ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ | | 19.05
|
| ÑÅÍÍÛ ËÈÑÒÜß 50à ¹1 (ÈÂÀÍ-×ÀÉ ÇÀÎ, ÐÎÑÑÈß) | ÈÂÀÍ-×ÀÉ ÇÀÎ | | 17.68
|
| ÑÅÍÍÛ ÝÊÑÒÐÀÊÒ ÒÀÁ. 300ÌÃ ¹10 (ÂÈÔÈÒÅÕ ÇÀÎ, ÐÎÑÑÈß) | ÂÈÔÈÒÅÕ ÇÀÎ | | 8.23
|
| ÑÅÏÒÎÃÀË ÒÀÁ. ¹20 (JADRAN, ÕÎÐÂÀÒÈß) | JADRAN | | 39.29
|
| ÑÅÏÒÎËÅÒÅ Ä ÏÀÑÒÈËÊÈ Á/ÑÀÕ. ¹30 (KRKA, ÑËÎÂÅÍÈß) | KRKA | | 51.19
|
| ÑÅÏÒÎËÅÒÅ ÍÅÎ ÏÀÑÒÈËÊÈ 1,2ÌÃ ¹18 (ËÈÌÎÍ) (KRKA, ÑËÎÂÅÍÈß) | KRKA | | 58.11
|
| ÑÅÏÒÎËÅÒÅ ÍÅÎ ÏÀÑÒÈËÊÈ 1,2ÌÃ ¹18 (ËÈÌÎÍ) (KRKA- ÐÓÑ, ÑËÎÂÅÍÈß) | KRKA- ÐÓÑ | | 62.34
|
| ÑÅÏÒÎËÅÒÅ ÍÅÎ ÏÀÑÒÈËÊÈ 1,2Ìà ¹18 (×ÅÐÅØÍß) (KRKA, ÑËÎÂÅÍÈß) | KRKA | | 62.29
|
| ÑÅÏÒÎËÅÒÅ ÍÅÎ ÏÀÑÒÈËÊÈ 1,2Ìà ¹18 (ßÁËÎÊÎ) (KRKA, ÑËÎÂÅÍÈß) | KRKA | | 58.17
|
| ÑÅÏÒÎËÅÒÅ ÏÀÑÒÈËÊÈ ¹30 (KRKA, ÑËÎÂÅÍÈß) | KRKA | | 64.25
|
| ÑÅÏÒÎËÅÒÅ ÏËÞÑ ÏÀÑÒÈËÊÈ ¹18 (KRKA, ÑËÎÂÅÍÈß) | KRKA | | 67.84
|
| ÑÅÐÅÒÈÄ ÀÝÐÎÇÎËÜ 0,25ÌÃ/125ÌÊÃ 120ÄÎÇ ¹1 (GLAXO SMITH KLINE, ÏÎËÜØÀ) | GLAXO SMITH KLINE | | 1361.6
|
| ÑÅÐÅÒÈÄ ÀÝÐÎÇÎËÜ 0,25ÌÃ/250ÌÊÃ 120ÄÎÇ ¹1 (GLAXO SMITH KLINE, ÏÎËÜØÀ) | GLAXO SMITH KLINE | | 2078.42
|
| ÑÅÐÅÒÈÄ ÀÝÐÎÇÎËÜ 0,25ÌÃ/50ÌÊÃ 120ÄÎÇ ¹1 (GLAXO SMITH KLINE) | GLAXO SMITH KLINE | | 1044.89
|
| ÑÅÐÅÒÈÄ ÌÓËÜÒÈÄÈÑÊ ÏÎÐ.Ä/ÈÍÃ.ÄÎÇÈÐ. 50ÌÊÃ/0,1ÌÃ 60ÄÎÇ ¹1 (GLAXO SMITH KLINE, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | GLAXO SMITH KLINE | | 1106.11
|
| ÑÅÐÅÒÈÄ ÌÓËÜÒÈÄÈÑÊ ÏÎÐ.Ä/ÈÍÃ.ÄÎÇÈÐ. 50ÌÊÃ/0,25ÌÃ 60ÄÎÇ ¹1 (GLAXO SMITH KLINE, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | GLAXO SMITH KLINE | | 1457.87
|
| ÑÅÐÌÈÎÍ ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍ. 4ÌÃ ¹4 Ñ Ð-ËÅÌ (PHARMACIA ITALIA, ÈÒÀËÈß) | PHARMACIA ITALIA | | 881.08
|
| ÑÅÐÌÈÎÍ ÒÀÁ. Ï/Î 10ÌÃ ¹50 (PHARMACIA ITALIA, ÈÒÀËÈß) | PHARMACIA ITALIA | | 280.02
|
| ÑÅÐÌÈÎÍ ÒÀÁ. Ï/Î 5ÌÃ ¹30 (PHARMACIA ITALIA, ÈÒÀËÈß) | PHARMACIA ITALIA | | 150.29
|
| ÑÅÐÍÀß ÌÀÇÜ ÏÐÎÑÒÀß 25Ã ¹1 (ÒÂÅÐÑÊÀß ÔÀÐÌÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÒÂÅÐÑÊÀß ÔÀÐÌÔÀÁÐÈÊÀ | | 6.57
|
| ÑÅÐÎÊÂÅËÜ ÒÀÁ. Ï/Î 100ÌÃ ¹60 (ASTRA ZENECA, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | ASTRA ZENECA | | 2838.59
|
| ÑÅÐÎÊÂÅËÜ ÒÀÁ. Ï/Î 200ÌÃ ¹60 (ASTRA ZENECA, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | ASTRA ZENECA | | 3647.05
|
| ÑÅÐÎÊÂÅËÜ ÒÀÁ. Ï/Î 25ÌÃ ¹60 (ASTRA ZENECA, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | ASTRA ZENECA | | 1503.67
|
| ÑÅÒÅÃÈÑ ÒÀÁ. 2ÌÃ ¹30 (EGIS, ÂÅÍÃÐÈß) | EGIS | | 347.62
|
| ÑÅÒÅÃÈÑ ÒÀÁ. 5ÌÃ ¹30 (EGIS, ÂÅÍÃÐÈß) | EGIS | | 652.48
|
| ÑÈÀËÈÑ ÒÀÁ. Ï/Î 20ÌÃ ¹1 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | ELI LILLY | | 536.8
|
| ÑÈÀËÈÑ ÒÀÁ. Ï/Î 20ÌÃ ¹2 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | ELI LILLY | | 983.05
|
| ÑÈÀËÈÑ ÒÀÁ. Ï/Î 20ÌÃ ¹4 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | ELI LILLY | | 1874.71
|
| ÑÈÁÀÇÎÍ ÒÀÁ. 5ÌÃ ¹20 (ÌÎÑÊÎÂÑÊÈÉ ÝÍÄÎÊÐÈÍÍÛÉ ÇÀÂÎÄ, ÐÎÑÑÈß) | ÌÎÑÊÎÂÑÊÈÉ ÝÍÄÎÊÐÈÍÍÛÉ ÇÀÂÎÄ | | 12.78
|
| ÑÈÁÀÇÎÍ ÒÀÁ. 5ÌÃ ¹20 (ÎÐÃÀÍÈÊÀ, ÐÎÑÑÈß) | ÎÐÃÀÍÈÊÀ | | 11.11
|
| ÑÈÁÅÊÒÀÍ ÒÀÁ. ¹30 (ÔÀÐÌÖÅÍÒÐ ÂÈËÀÐ, ÐÎÑÑÈß) | ÔÀÐÌÖÅÍÒÐ ÂÈËÀÐ | | 64.62
|
| ÑÈÄÍÎÔÀÐÌ ÒÀÁ. 2ÌÃ ¹30 (SOPHARMA, ÁÎËÃÀÐÈß) | SOPHARMA | | 67.41
|
| ÑÈËÅÑÒ ÒÀÁ. ¹21 (JANSSEN CILAG, ØÂÅÉÖÀÐÈß) | JANSSEN CILAG | | 252.97
|
| ÑÈËÈÊÎÍÎÂÀß ÑÎÑÊÀ Ð.M 2ØÒ. (ÌÅÄÅËÀ, ØÂÅÉÖÀÐÈß) | ÌÅÄÅËÀ | | 185.54
|
| ÑÈËÈÌÀÐ ÒÀÁ. 100ÌÃ ¹30 (ÂÈËÀÐ, ÐÎÑÑÈß) | ÂÈËÀÐ | | 45.03
|
| ÑÈÌÁÀËÒÀ ÊÀÏÑ. 30ÌÃ ¹14 (ELI LILLY, ÈÑÏÀÍÈß) | ELI LILLY | | 777.87
|
| ÑÈÌÁÀËÒÀ ÊÀÏÑ. 60ÌÃ ¹14 (ELI LILLY, ÈÑÏÀÍÈß) | ELI LILLY | | 786.86
|
| ÑÈÌÁÀËÒÀ ÊÀÏÑ. 60ÌÃ ¹28 (ELI LILLY, ÑØÀ) | ELI LILLY | | 1693.38
|
| ÑÈÌÁÈÊÎÐÒ ÒÓÐÁÓÕÀËÅÐ ÏÎÐÎØÎÊ 160+4,5ÌÊÃ/Ä 60ÄÎ3 ¹1 (ASTRA ZENECA, ØÂÅÖÈß) | ASTRA ZENECA | | 1215.11
|
| ÑÈÌÁÈÊÎÐÒ ÒÓÐÁÓÕÀËÅÐ ÏÎÐÎØÎÊ 80+4,5ÌÊÃ/Ä 60ÄÎÇ ¹1 (ASTRA ZENECA, ØÂÅÖÈß) | ASTRA ZENECA | | 931.16
|
| ÑÈÌÂÀÃÅÊÑÀË ÒÀÁ. Ï/Î 20ÌÃ ¹30 (SALUTAS PHARMA GMBH, ÃÅÐÌÀÍÈß) | SALUTAS PHARMA GMBH | | 303.97
|
| ÑÈÌÂÀÊÀÐÄ ÒÀÁ. Ï/Î 10Ìà ¹28 (ZENTIVA/LECHIVA, ×ÅÕÈß) | ZENTIVA/LECHIVA | | 211.72
|
| ÑÈÌÂÀÊÀÐÄ ÒÀÁ. Ï/Î 20Ìà ¹28 (ZENTIVA/LECHIVA, ×ÅÕÈß) | ZENTIVA/LECHIVA | | 140.15
|
| ÑÈÌÂÀÑÒÀÒÈÍ ÒÀÁ. 10ÌÃ ¹30 (ÀËÑÈ ÔÀÐÌÀ, ÐÎÑÑÈß) | ÀËÑÈ ÔÀÐÌÀ | | 118.79
|
| ÑÈÌÂÀÑÒÎË ÒÀÁ. 10ÌÃ ¹28 (GEDEON RICHTER, ÐÓÌÛÍÈß) | GEDEON RICHTER | | 207.78
|
| ÑÈÌÂÎÐ ÒÀÁ. Ï/Î 10ÌÃ ¹30 (RANBAXY, ÈÍÄÈß) | RANBAXY | | 182.94
|
| ÑÈÌÂÎÐ ÒÀÁ. Ï/Î 20ÌÃ ¹30 (RANBAXY, ÈÍÄÈß) | RANBAXY | | 286.49
|
| ÑÈÌÃÀË ÒÀÁ. Ï/Î 10Ìà ¹28 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 244.66
|
| ÑÈÌÃÀË ÒÀÁ. Ï/Î 10Ìà ¹84 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 575.98
|
| ÑÈÌÃÀË ÒÀÁ. Ï/Î 20Ìà ¹28 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 334.34
|
| ÑÈÌÃÀË ÒÀÁ. Ï/Î 20Ìà ¹84 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 745.41
|
| ÑÈÌÃÀË ÒÀÁ. Ï/Î 40Ìà ¹28 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 592.97
|
| ÑÈÌËÎ ÒÀÁ. Ï/Î 10ÌÃ ¹28 (IPCA LABORATORIES, ÈÍÄÈß) | IPCA LABORATORIES | | 168.15
|
| ÑÈÍÀÔËÀÍ ËÈÍÈÌÅÍÒ 0,025% 15Ã ¹1 (ÍÈÆÔÀÐÌ, ÐÎÑÑÈß) | ÍÈÆÔÀÐÌ | | 18.42
|
| ÑÈÍÀÔËÀÍ ÌÀÇÜ 0,025% 15Ã ¹1 (ÌÓÐÎÌÑÊÈÉ ÏÐÈÁÎÐÎÑÒÐÎÈÒÅËÜÍÛÉ Ç-Ä, ÐÎÑÑÈß) | ÌÓÐÎÌÑÊÈÉ ÏÐÈÁÎÐÎÑÒÐÎÈÒÅËÜÍÛÉ Ç-Ä | | 9.78
|
| ÑÈÍÃÓËßÐ ÒÀÁ. Ï/Î 10Ìà ¹14 (MERCK SHARP & DOHME, ÍÈÄÅÐËÀÍÄÛ) | MERCK SHARP & DOHME | | 898.06
|
| ÑÈÍÅÊÎÄ ÊÀÏËÈ 5ÌÃ/ÌË 20ÌË ¹1 (NOVARTIS CONSUMER HEALTH, ØÂÅÉÖÀÐÈß) | NOVARTIS CONSUMER HEALTH | | 246.39
|
| ÑÈÍÅÊÎÄ ÑÈÐÎÏ 1,5ÌÃ/ÌË 200ÌË ¹1 (NOVARTIS CONSUMER HEALTH, ØÂÅÉÖÀÐÈß) | NOVARTIS CONSUMER HEALTH | | 224.67
|
| ÑÈÍÒÎÌÈÖÈÍ ÑÓÏÏ. ÂÀÃÈÍÀËÜÍÛÅ 250ÌÃ ¹10 (ÁÈÎÑÈÍÒÅÇ, ÐÎÑÑÈß) | ÁÈÎÑÈÍÒÅÇ | | 14.66
|
| ÑÈÍÒÎÌÈÖÈÍ ÑÓÏÏ. ÂÀÃÈÍÀËÜÍÛÅ 250ÌÃ ¹10 (ÄÀËÜÕÈÌÔÀÐÌ ÎÀÎ, ÐÎÑÑÈß) | ÄÀËÜÕÈÌÔÀÐÌ ÎÀÎ | | 14.98
|
| ÑÈÍÒÎÌÈÖÈÍÀ ËÈÍÈÌÅÍÒ ËÈÍÈÌÅÍÒ 10% 25Ã ¹1 (ÇÅËÅÍÀß ÄÓÁÐÀÂÀ, ÐÎÑÑÈß) | ÇÅËÅÍÀß ÄÓÁÐÀÂÀ | | 11.59
|
| ÑÈÍÓÏÐÅÒ ÄÐÀÆÅ ¹50 (BIONORICA- ARZNEIMITTEL, ÃÅÐÌÀÍÈß) | BIONORICA- ARZNEIMITTEL | | 181.63
|
| ÑÈÍÓÏÐÅÒ ÊÀÏËÈ 100ÌË ¹1 (BIONORICA- ARZNEIMITTEL, ÃÅÐÌÀÍÈß) | BIONORICA- ARZNEIMITTEL | | 175.38
|
| ÑÈÍÓÔÎÐÒÅ ËÈÎÔ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍÒÐÀÍÀÇ.ÂÂÅÄ. 50ÌÃ ¹1 Ñ Ð-ËÅÌ (LABIANA FARMACEUTICA, ÈÑÏÀÍÈß) | LABIANA FARMACEUTICA | | 1289.14
|
| ÑÈÎÔÎÐ 1000 ÒÀÁ. 1000ÌÃ ¹60 (BERLIN-CHEMIE, ÃÅÐÌÀÍÈß) | BERLIN-CHEMIE | | 385.51
|
| ÑÈÎÔÎÐ 500 ÒÀÁ. 500ÌÃ ¹60 (BERLIN-CHEMIE, ÃÅÐÌÀÍÈß) | BERLIN-CHEMIE | | 224.56
|
| ÑÈÎÔÎÐ 850 ÒÀÁ. 850ÌÃ ¹60 (BERLIN-CHEMIE, ÃÅÐÌÀÍÈß) | BERLIN-CHEMIE | | 294.58
|
| ÑÈÐÄÀËÓÄ ÒÀÁ. 2ÌÃ ¹30 (NOVARTIS PHARMA, ÃÅÐÌÀÍÈß) | NOVARTIS PHARMA | | 204.93
|
| ÑÈÐÄÀËÓÄ ÒÀÁ. 2ÌÃ ¹30 (NOVARTIS SAGLIK GIDA VE TARIM, ÒÓÐÖÈß) | NOVARTIS SAGLIK GIDA VE TARIM | | 202.89
|
| ÑÈÐÄÀËÓÄ ÒÀÁ. 4ÌÃ ¹30 (NOVARTIS SAGLIK GIDA VE TARIM, ÒÓÐÖÈß) | NOVARTIS SAGLIK GIDA VE TARIM | | 301.67
|
| ÑÈÐÄÀËÓÄ ÒÀÁ. 4ÌÃ ¹30 (NOVARTIS/SANDOZ, ÒÓÐÖÈß) | NOVARTIS/SANDOZ | | 302.39
|
| ÑÈÐÎÏ ÇÅËÅÍÎÃÎ ×Àß 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 45.77
|
| ÑÈÐÎÏ ÊËÞÊÂÀ ÍÀ ÔÐÓÊÒÎÇÅ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 55.32
|
| ÑÈÐÎÏ ÌÀËÈÍÀ ÍÀ ÔÐÓÊÒÎÇÅ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 53.61
|
| ÑÈÐÎÏ ÎÁËÅÏÈÕÀ ÍÀ ÔÐÓÊÒÎÇÅ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 53.71
|
| ÑÈÐÎÏ ÏËÎÄÎÂ ØÈÏÎÂÍÈÊÀ Ñ ËÈÌ. È ×.ÑÌÎÐÎÄÈÍÎÉ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 42.44
|
| ÑÈÐÎÏ ÏÐÈ ÊÀØËÅ 100ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 40.18
|
| ÑÈÐÎÏ ÏÐÈ ÏÐÎÑÒÓÄÅ 100ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 40.14
|
| ÑÈÐÎÏ ÏÓÑÒÛÐÍÈÊÀ 100ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 12.4
|
| ÑÈÐÎÏ ×ÅÐÍ.ÑÌÎÐÎÄÈÍÀ ÍÀ ÔÐÓÊÒÎÇÅ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 50.44
|
| ÑÈÐÎÏ ×ÅÐÍÈÊÀ ÍÀ ÔÐÓÊÒÎÇÅ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 55.32
|
| ÑÈÐÎÏ ×ÅÐÍÈÊÈ Ñ ÝÕÈÍÀÖÅÅÉ È ØÈÏÎÂÍÈÊÎÌ 100ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 62.5
|
| ÑÈÐÎÏ ØÈÏÎÂÍÈÊ ÍÀ ÔÐÓÊÒÎÇÅ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 45.8
|
| ÑÈÐÎÏ ØÈÏÎÂÍÈÊÀ 100ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 19.55
|
| ÑÈÐÎÏ ßÃÎÄ ÂÈØÍÈ Ñ ×ÅÐÍ.ÑÌÎÐÎÄÈÍÎÉ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 46.35
|
| ÑÈÐÎÏ ßÃÎÄ ÊËÞÊÂÛ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 46.35
|
| ÑÈÐÎÏ ßÃÎÄ ÌÀËÈÍÛ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß) | ÀÑÒÐÎÌÀÐ | | 49.11
|
| ÑÈÑÒÅÉÍ ÊÀÏËÈ ÃËÀÇÍÛÅ 10ÌË ¹1 (ALCON COUVEUR S.A., ÈÑÏÀÍÈß) | ALCON COUVEUR S.A. | | 264.63
|
| ÑÈÑÒÅÌÀ ÄËß ÐÀÑÒÂÎÐÎÂ ÊD ¹1 (HUAFU, ÊÈÒÀÉ) | HUAFU | | 4.92
|
| ÑÈÑÒÅÌÀ ÄËß ÐÀÑÒÂÎÐÎÂ ÊD ¹1 (HUAFU, ÊÈÒÀÉ) | HUAFU | | 4.92
|
| ÑÈÑÒÅÌÀ ÄËß ÐÀÑÒÂÎÐÎÂ ÊD ¹1 (WUXI YUSHOU MEDICAL APPLIANCES, ÊÈÒÀÉ) | WUXI YUSHOU MEDICAL APPLIANCES | | 4.8
|
| ÑÈÑÒÅÌÀ ÈÍÔÓÇ. Ä/ÏÅÐÅË. Ð-ÐÎÂ SFM ¹25 (SFM HOSPITAL GMBH, ÃÅÐÌÀÍÈß) | SFM HOSPITAL GMBH | | 176.1
|
| ÑÈÑÒÅÌÀ ÈÍÔÓÇ. Ä/ÏÅÐÅË. Ð-ÐÎÂ ¹1 (JIANGXI HONGDA MEDICAL EQUIPMENT GROUP, ÊÈÒÀÉ) | JIANGXI HONGDA MEDICAL EQUIPMENT GROUP | | 4.86
|
| ÑÈÑÒÅÌÀ ÈÍÔÓÇ. Ä/ÏÅÐÅË. Ð-ÐÎÂ Ñ ÏËÀÑÒ. ØÈÏÎÌ ¹1 (VOGT MEDICAL, ÃÅÐÌÀÍÈß) | VOGT MEDICAL | | 4.78
|
| ÑÈÑÒÅÌÀ ÊÎÐÌËÅÍÈß SNS (ÌÅÄÅËÀ, ØÂÅÉÖÀÐÈß) | ÌÅÄÅËÀ | | 1122.98
|
| ÑÈÑÒÅÌÀ ÒÐÀÍÑÔÓÇÈÎÍ. Ä/ÏÅÐÅË. ÊÐÎÂÈ SFM ¹25 (SFM HOSPITAL GMBH, ÃÅÐÌÀÍÈß) | SFM HOSPITAL GMBH | | 119.93
|
| ÑÈÑÒÅÌÀ ÒÐÀÍÑÔÓÇÈÎÍ. Ä/ÏÅÐÅË. ÊÐÎÂÈ SFM ¹25 (SFM HOSPITAL GMBH, ÃÅÐÌÀÍÈß) | SFM HOSPITAL GMBH | | 257.39
|
| ÑÈÑÒÅÌÀ ÒÐÀÍÑÔÓÇÈÎÍ. Ä/ÏÅÐÅË. ÊÐÎÂÈ Ñ ÏËÀÑÒ. ØÈÏÎÌ ¹1 (VOGT MEDICAL, ÃÅÐÌÀÍÈß) | VOGT MEDICAL | | 9.44
|
| ÑÊÈÍ-ÊÀÏ ÀÝÐÎÇÎËÜ 0,2% 70Ã ¹1 (CHEMINOVA, ÈÑÏÀÍÈß) | CHEMINOVA | | 1657.91
|
| ÑÊÈÍ-ÊÀÏ ÃÅËÜ Ä/ÄÓØÀ 150ÌË (CHEMINOVA, ÈÑÏÀÍÈß) | CHEMINOVA | | 361.67
|
| ÑÊÈÍ-ÊÀÏ ÊÐÅÌ 0,2% 50Ã ¹1 (CHEMINOVA, ÈÑÏÀÍÈß) | CHEMINOVA | | 1034.89
|
| ÑÊÈÍ-ÊÀÏ ØÀÌÏÓÍÜ 150ÌË ¹1 (CHEMINOVA, ÈÑÏÀÍÈß) | CHEMINOVA | | 658.03
|
| ÑÊÈÍÎÐÅÍ ÃÅËÜ 15% 30Ã ¹1 (INTENDIS MANUFACTURING, ÃÅÐÌÀÍÈß) | INTENDIS MANUFACTURING | | 634.34
|
| ÑÊÈÍÎÐÅÍ ÊÐÅÌ 20% 30Ã ¹1 (INTENDIS MANUFACTURING, ÈÒÀËÈß) | INTENDIS MANUFACTURING | | 606.09
|
| ÑÊÈÏÀÐ ÄÂÈÆÅÍÈÅ ÝÌÓËÜÑÈß Ä/ÂÀÍÍ ÑÌÅØÀÍÍÀß 0,25Ë (ÇÅËÄÈÑ, ÐÎÑÑÈß) | ÇÅËÄÈÑ | | 190.8
|
| ÑÊÈÏÀÐ ÑÊÈÏÈÄÀÐÍÀß ÝÌÓËÜÑÈß ÁÅËÀß 0,2Ë (Ð.ÊÎÑÌÅÒÈÊ, ÐÎÑÑÈß) | Ð.ÊÎÑÌÅÒÈÊ | | 172.74
|
| ÑÊÈÏÀÐ ÑÊÈÏÈÄÀÐÍÀß ÝÌÓËÜÑÈß ÁÅËÀß 0,5Ë (ÇÅËÄÈÑ, ÐÎÑÑÈß) | ÇÅËÄÈÑ | | 255.27
|
| ÑÊÈÏÀÐ ÑÊÈÏÈÄÀÐÍÛÉ Ð-Ð ÆÅËÒÛÉ 0,2Ë (Ð.ÊÎÑÌÅÒÈÊ, ÐÎÑÑÈß) | Ð.ÊÎÑÌÅÒÈÊ | | 193.2
|
| ÑÊÈÏÀÐ ÑÊÈÏÈÄÀÐÍÛÉ Ð-Ð ÆÅËÒÛÉ 0,5Ë (ÇÅËÄÈÑ, ÐÎÑÑÈß) | ÇÅËÄÈÑ | | 299.37
|
| ÑÊÈÏÀÐ ÒÎÍÓÑ ÝÌÓËÜÑÈß Ä/ÂÀÍÍ ÑÌÅØÀÍÍÀß 0,25Ë (ÇÅËÄÈÑ, ÐÎÑÑÈß) | ÇÅËÄÈÑ | | 184.5
|
| ÑÊÈÏÀÐ ÔÈÃÓÐÀ ÝÌÓËÜÑÈß Ä/ÂÀÍÍ ÑÌÅØÀÍÍÀß 0,25Ë (ÇÅËÄÈÑ, ÐÎÑÑÈß) | ÇÅËÄÈÑ | | 184.5
|
| ÑÊÈÏÈÄÀÐÍÀß ÌÀÇÜ ÌÀÇÜ 25Ã ¹1 (ÒÓËÜÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÒÓËÜÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ | | 10.63
|
| ÑÊÐÀÁ ÌßÃÊÈÉ Ñ ÝÊÑÒÐ.ÏËÀÖ. Ä/ÊÎÆÈ ËÈÖÀ 150ÌË (COSMEDIC LABORATORY, ÐÎÑÑÈß) | COSMEDIC LABORATORY | | 111.16
|
| ÑÊÐÀÁ ÌßÃÊÈÉ Ñ ÝÊÑÒÐ.ÏËÀÖ. Ä/ÊÎÆÈ ËÈÖÀ 150ÌË (ÝÂÈÍÀËÜ ÎÎÎ, ÐÎÑÑÈß) | ÝÂÈÍÀËÜ ÎÎÎ | | 94.07
|
| ÑËÀÁÈËÅÍ ÊÀÏËÈ 0,75% 15ÌË ¹1 (ËÝÍÑ-ÔÀÐÌ, ÐÎÑÑÈß) | ËÝÍÑ-ÔÀÐÌ | | 94.36
|
| ÑËÅÇÀ ÍÀÒÓÐÀËÜÍÀß ÊÀÏËÈ ÃËÀÇÍÛÅ 15ÌË ¹1 (ALCON COUVEUR S.A., ÁÅËÜÃÈß) | ALCON COUVEUR S.A. | | 129.88
|
| ÑÌÅÊÒÀ-ÀÏÅËÜÑÈÍ ÏÎÐÎØÎÊ 3Ã ¹10 (BEAUFOUR IPSEN, ÔÐÀÍÖÈß) | BEAUFOUR IPSEN | | 125.59
|
| ÑÌÅÊÒÀ-ÀÏÅËÜÑÈÍ ÏÎÐÎØÎÊ 3Ã ¹30 (BEAUFOUR IPSEN, ÔÐÀÍÖÈß) | BEAUFOUR IPSEN | | 291.2
|
| ÑÌÅÑÜ ÄËß ÈÍÃÀËßÖÈÉ Ð-Ð Ä/ÈÍÃ. 40ÌË ¹1 (ÌÎÑÊÎÂÑÊÀß ÔÀÐÌ.Ô-ÊÀ, ÐÎÑÑÈß) | ÌÎÑÊÎÂÑÊÀß ÔÀÐÌ.Ô-ÊÀ | | 7.64
|
| ÑÎËÈÀÍ ÒÀÁ. Ï/Î 200ÌÃ ¹30 (SANOFI-WINTHROP, ÔÐÀÍÖÈß) | SANOFI-WINTHROP | | 3011.53
|
| ÑÎËÈÀÍ ÒÀÁ. Ï/Î 400ÌÃ ¹30 (SANOFI-WINTHROP, ÔÐÀÍÖÈß) | SANOFI-WINTHROP | | 5672.1
|
| ÑÎËÊÎÂÀÃÈÍ Ð-Ð Ä/ÌÅÑÒÍ.ÏÐÈÌ. 0,5ÌË ¹2 (VALEANT PHARMACEUTICALS, ØÂÅÉÖÀÐÈß) | VALEANT PHARMACEUTICALS | | 533.57
|
| ÑÎËÊÎÑÅÐÈË ÃÅËÜ 10% 20Ã ¹1 (I C N SWITZERLAND, ØÂÅÉÖÀÐÈß) | I C N SWITZERLAND | | 97.54
|
| ÑÎËÊÎÑÅÐÈË ÃÅËÜ 20Ã ¹1 (LEGACY PHARMACEUTICALS SWITZERLAND, ØÂÅÉÖÀÐÈß) | LEGACY PHARMACEUTICALS SWITZERLAND | | 95.26
|
| ÑÎËÊÎÑÅÐÈË ÃÅËÜ ÃËÀÇÍÎÉ 20% 5Ã ¹1 (LEGACY PHARMACEUTICALS SWITZERLAND, ØÂÅÉÖÀÐÈß) | LEGACY PHARMACEUTICALS SWITZERLAND | | 168.52
|
| ÑÎËÊÎÑÅÐÈË ÄÅÍÒÀË ÏÀÑÒÀ 5% 5Ã ¹1 (I C N SWITZERLAND, ØÂÅÉÖÀÐÈß) | I C N SWITZERLAND | | 172.59
|
| ÑÎËÊÎÑÅÐÈË ÄÅÍÒÀË ÏÀÑÒÀ 5% 5Ã ¹1 (VALEANT PHARMACEUTICALS, ØÂÅÉÖÀÐÈß) | VALEANT PHARMACEUTICALS | | 169.77
|
| ÑÎËÊÎÑÅÐÈË ÌÀÇÜ 5% 20Ã ¹1 (I C N SWITZERLAND, ØÂÅÉÖÀÐÈß) | I C N SWITZERLAND | | 87.25
|
| ÑÎËÊÎÑÅÐÈË ÌÀÇÜ 5% 20Ã ¹1 (LEGACY PHARMACEUTICALS SWITZERLAND, ØÂÅÉÖÀÐÈß) | LEGACY PHARMACEUTICALS SWITZERLAND | | 89.32
|
| ÑÎËÎÄÊÈ ÊÎÐÅÍÜ 50à ¹1 (ÈÂÀÍ-×ÀÉ ÇÀÎ, ÐÎÑÑÈß) | ÈÂÀÍ-×ÀÉ ÇÀÎ | | 16.76
|
| ÑÎËÎÄÊÈ ÊÎÐÅÍÜ 50Ã ¹1 (ÊÐÀÑÍÎÃÎÐÑÊËÅÊÑÐÅÄÑÒÂÀ ÎÀÎ, ÐÎÑÑÈß) | ÊÐÀÑÍÎÃÎÐÑÊËÅÊÑÐÅÄÑÒÂÀ ÎÀÎ | | 25.43
|
| ÑÎËÎÄÊÈ ÊÎÐÅÍÜ 50Ã ¹1 (ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ, ÐÎÑÑÈß) | ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ | | 14.91
|
| ÑÎËÎÄÊÈ ÊÎÐÍÈ 50Ã ¹1 (ÇÄÎÐÎÂÜÅ, ÐÎÑÑÈß) | ÇÄÎÐÎÂÜÅ | | 19.96
|
| ÑÎËÎÄÊÈ ÊÎÐÍß ÑÈÐÎÏ ÑÈÐÎÏ 100Ã ¹1 (ÁÝÃÐÈÔ ÎÎÎ, ÐÎÑÑÈß) | ÁÝÃÐÈÔ ÎÎÎ | | 11.67
|
| ÑÎËÎÄÊÈ ÊÎÐÍß ÑÈÐÎÏ ÑÈÐÎÏ 100Ã ¹1 (ÑÀÌÀÐÀÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÑÀÌÀÐÀÌÅÄÏÐÎÌ | | 10.26
|
| ÑÎËÎÄÊÈ ÊÎÐÍß ÑÈÐÎÏ ÑÈÐÎÏ 100Ã ¹1 (ÒÂÅÐÑÊÀß ÔÀÐÌÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÒÂÅÐÑÊÀß ÔÀÐÌÔÀÁÐÈÊÀ | | 12.78
|
| ÑÎËÏÀÄÅÈÍ ÒÀÁ. ¹12 ÏËÀÑÒ.ÓÏ. (GLAXO SMITH KLINE, ÈÐËÀÍÄÈß) | GLAXO SMITH KLINE | | 69.45
|
| ÑÎËÏÀÄÅÈÍ ÒÀÁ. ¹8 (GLAXO SMITH KLINE, ÈÐËÀÍÄÈß) | GLAXO SMITH KLINE | | 58.48
|
| ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÄÓØÈÖÀ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 13.52
|
| ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÇÂÅÐÎÁÎÉ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 14.39
|
| ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÊÀËÅÍÄÓËÀ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 13.52
|
| ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÊÐÀÏÈÂÀ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 13.25
|
| ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÎÁËÅÏÈÕÀ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 14.39
|
| ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÏÎËÛÍÜ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 14.39
|
| ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÐÎÌÀØÊÀ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 13.52
|
| ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÒÛÑß×ÅËÈÑÒÍÈÊ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 14.39
|
| ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ×ÈÑÒÎÒÅË 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 14.39
|
| ÑÎËÜ "ÌÎÐÑÊÈÅ ÂÎÄÎÐÎÑËÈ" ËÀÌÈÍÀÐÈß 500Ã (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 15.17
|
| ÑÎËÜ "ÌÎÐÑÊÈÅ ÂÎÄÎÐÎÑËÈ" ÔÓÊÓÑ 500Ã (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 15.17
|
| ÑÎËÜ "ÖÂÅÒÎ×ÍÀß" ÆÀÑÌÈÍ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 13.32
|
| ÑÎËÜ "ÖÂÅÒÎ×ÍÀß" ÐÎÇÀ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 13.32
|
| ÑÎËÜ "ÖÂÅÒÎ×ÍÀß" ÑÈÐÅÍÜ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 13.32
|
| ÑÎËÜ ÉÎÄÎÁÐÎÌÍÀß Ñ ÌÈÊÐÎÝËÅÌÅÍÒÀÌÈ (0,7 ÊÃ Ï/ÝÒ) (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 25.32
|
| ÑÎËÜ ÌÎÐ. ÀÐÎÌ. ÄÓØÈÖÀ 0,5ÊÃ (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 12.52
|
| ÑÎËÜ ÌÎÐ. ÀÐÎÌ. ËÈÌÎÍ 0,5ÊÃ (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 15.17
|
| ÑÎËÜ ÌÎÐ. ÀÐÎÌ. ÌßÒÀ 0,5ÊÃ (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 13.2
|
| ÑÎËÜ ÌÎÐ. ÀÐÎÌ. ÐÎÇÌÀÐÈÍ 0,5ÊÃ (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 15.17
|
| ÑÎËÜ ÌÎÐ. ÏÐÈÐÎÄÍÀß 1ÊÃ (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß) | ÓÐÀËÌÅÄÏÐÎÌ | | 15.09
|
| ÑÎÌÍÎË ÒÀÁ. Ï/Î 7,5ÌÃ ¹20 (GRINDEX, ËÀÒÂÈß) | GRINDEX | | 161.96
|
| ÑÎÍÀÏÀÊÑ ÄÐÀÆÅ 10ÌÃ ¹60 (JELFA, ÏÎËÜØÀ) | JELFA | | 135.1
|
| ÑÎÍÀÏÀÊÑ ÄÐÀÆÅ 25ÌÃ ¹60 (JELFA, ÏÎËÜØÀ) | JELFA | | 227.28
|
| ÑÎÐÁÈÒ ÏÈÙÅÂÎÉ ÏÎÐÎØÎÊ 500Ã ¹1 (ÌÀÐÁÈÎÔÀÐÌ, ÐÎÑÑÈß) | ÌÀÐÁÈÎÔÀÐÌ | | 33.97
|
| ÑÎÐÁÈÔÅÐ ÄÓÐÓËÅÑ ÒÀÁ. Ï/Î 320ÌÃ ¹30 (EGIS, ÂÅÍÃÐÈß) | EGIS | | 172.03
|
| ÑÎÐÁÈÔÅÐ ÄÓÐÓËÅÑ ÒÀÁ. Ï/Î 320ÌÃ ¹50 (EGIS, ÂÅÍÃÐÈß) | EGIS | | 199.81
|
| ÑÎÑÍÛ ÏÎ×ÊÈ 50à ¹1 (ÇÄÎÐÎÂÜÅ, ÐÎÑÑÈß) | ÇÄÎÐÎÂÜÅ | | 64.25
|
| ÑÎÑÍÛ ÏÎ×ÊÈ 50à ¹1 (ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ, ÐÎÑÑÈß) | ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ | | 38.97
|
| ÑÎÒÀÃÅÊÑÀË ÒÀÁ. 160ÌÃ ¹20 (HEXAL A.G./SALUTAS PHARMA GMBH, ÃÅÐÌÀÍÈß) | HEXAL A.G./SALUTAS PHARMA GMBH | | 134.01
|
| ÑÎÒÀÃÅÊÑÀË ÒÀÁ. 80ÌÃ ¹20 (HEXAL A.G./SALUTAS PHARMA GMBH, ÃÅÐÌÀÍÈß) | HEXAL A.G./SALUTAS PHARMA GMBH | | 80.9
|
| ÑÎÒÀËÅÊÑ ÒÀÁ. 160ÌÃ ¹30 (BRISTOL MYERS SQUIBB, ÔÐÀÍÖÈß) | BRISTOL MYERS SQUIBB | | 122.02
|
| ÑÎÔÐÀÄÅÊÑ ÊÀÏËÈ 5ÌË ¹1 (AVENTIS PHARMA, ÈÍÄÈß) | AVENTIS PHARMA | | 104.24
|
| ÑÎÔÜß (Ï×ÅËÈÍÛÉ ßÄ) ÊÐÅÌ Ä/ÒÅËÀ 75ÌË (ÔÎÐÀ-ÔÀÐÌ, ÐÎÑÑÈß) | ÔÎÐÀ-ÔÀÐÌ | | 75.93
|
| ÑÎÔÜß (ÝÊÑÒÐÀÊÒ ÏÈßÂÊÈ) ÊÐÅÌ Ä/ÍÎà 75ÌË (ÔÎÐÀ-ÔÀÐÌ, ÐÎÑÑÈß) | ÔÎÐÀ-ÔÀÐÌ | | 77.08
|
| ÑÏÀÇÌÀËÃÎÍ Ð-Ð Ä/ÈÍ. 2ÌË ¹10 (SOPHARMA, ÁÎËÃÀÐÈß) | SOPHARMA | | 121.11
|
| ÑÏÀÇÌÀËÃÎÍ Ð-Ð Ä/ÈÍ. 5ÌË ¹10 (SOPHARMA, ÁÎËÃÀÐÈß) | SOPHARMA | | 157.65
|
| ÑÏÀÇÌÀËÃÎÍ ÒÀÁ. ¹20 (BALKANPHARMA, ÁÎËÃÀÐÈß) | BALKANPHARMA | | 56.17
|
| ÑÏÀÇÌÀËÈÍ Ð-Ð ÄËß Â/Â È Â/Ì ÂÂÅÄ. 5ÌË ¹25 (TORRENT PHARMACEUTICALS, ÈÍÄÈß) | TORRENT PHARMACEUTICALS | | 258.64
|
| ÑÏÀÇÌÅÊÑ ÒÀÁ. 15ÌÃ ¹30 (DR. R. PFLEGER, ÃÅÐÌÀÍÈß) | DR. R. PFLEGER | | 307.41
|
| ÑÏÀÇÌÅÊÑ ÒÀÁ. 5ÌÃ ¹30 (DR. R. PFLEGER, ÃÅÐÌÀÍÈß) | DR. R. PFLEGER | | 148.61
|
| ÑÏÀÇÌÎË ÒÀÁ. 40ÌÃ ¹100 (ÔÀÐÌÑÒÀÍÄÀÐÒ ËÅÊÑÐÅÄÑÒÂÀ, ÐÎÑÑÈß) | ÔÀÐÌÑÒÀÍÄÀÐÒ ËÅÊÑÐÅÄÑÒÂÀ | | 69.23
|
| ÑÏÀÇÌÎË ÒÀÁ. 40ÌÃ ¹20 (ÔÀÐÌÑÒÀÍÄÀÐÒ-ËÅÊÑÐÅÄÑÒÂÀ, ÐÎÑÑÈß) | ÔÀÐÌÑÒÀÍÄÀÐÒ-ËÅÊÑÐÅÄÑÒÂÀ | | 20.23
|
| ÑÏÀÇÌÎÍÅÒ ÒÀÁ. 40ÌÃ ¹20 (KRKA- ÐÓÑ, ÐÎÑÑÈß) | KRKA- ÐÓÑ | | 43.11
|
| ÑÏÀÐÔËÎ ÒÀÁ. 200ÌÃ ¹6 (DR. REDDYS LAB., ÈÍÄÈß) | DR. REDDYS LAB. | | 292.83
|
| ÑÏÀÑÀÒÅËÜ ÁÀËÜÇÀÌ 30Ã (ËÞÌÈ, ÐÎÑÑÈß) | ËÞÌÈ | | 47.04
|
| ÑÏÅÖÈÀËÜÍÎÅ ÄÐ. ÌÅÐÖ ÁÜÞÒÈ 675ÌÃ ¹60 (MERZ-PHARMA, ÃÅÐÌÀÍÈß) | MERZ-PHARMA | | 482.59
|
| ÑÏÅÖÈÀËÜÍÎÅ ÄÐÀÆÅ ÌÅÐÖ ÄÐÀÆÅ 695ÌÃ ¹60 (MERZ-PHARMA, ÃÅÐÌÀÍÈß) | MERZ-PHARMA | | 414.14
|
| ÑÏÈÐÈÂÀ ÊÀÏÑ. Ñ ÏÎÐ.Ä/ÈÍÃ. 18ÌÊÃ ¹30 (BOEHRINGER INGELHEIM, ÃÅÐÌÀÍÈß) | BOEHRINGER INGELHEIM | | 2479.58
|
| ÑÏÈÐÈÂÀ ÊÀÏÑ. Ñ ÏÎÐ.Ä/ÈÍÃ. 18ÌÊÃ ¹30+ÈÍÃÀËßÒÎÐ (BOEHRINGER INGELHEIM, ÃÅÐÌÀÍÈß) | BOEHRINGER INGELHEIM | | 2394.64
|
| ÑÏÈÐÒ ÝÒÈËÎÂÛÉ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ.È ËÅÊ.ÔÎÐÌ 70% 100ÌË ¹1 (ÊÎÍÑÒÀÍÒÀ - ÔÀÐÌ, ÐÎÑÑÈß) | ÊÎÍÑÒÀÍÒÀ - ÔÀÐÌ | | 10.19
|
| ÑÏÈÐÒ ÝÒÈËÎÂÛÉ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ.È ËÅÊ.ÔÎÐÌ 95% 100ÌË ¹1 (ÊÎÍÑÒÀÍÒÀ - ÔÀÐÌ, ÐÎÑÑÈß) | ÊÎÍÑÒÀÍÒÀ - ÔÀÐÌ | | 10.76
|
| ÑÏÈÐÓËÈÍÀ ÂÝË ¹120 (Â-ÌÈÍ/ÝÊÎËÎÃÈß ÏÈÒÀÍÈß ÍÏÎ ÇÀÎ, ÐÎÑÑÈß) | Â-ÌÈÍ/ÝÊÎËÎÃÈß ÏÈÒÀÍÈß ÍÏÎ ÇÀÎ | | 192.5
|
| ÑÏÈÐÓËÈÍÀ ÂÝË ¹60 (ÝÊÎËÎÃÈß ÏÈÒÀÍÈß ÍÏÎ ÇÀÎ, ÐÎÑÑÈß) | ÝÊÎËÎÃÈß ÏÈÒÀÍÈß ÍÏÎ ÇÀÎ | | 110.19
|
| ÑÏËÀÒ JUNIOR ÇÀÏÀÄ Ç/Ï Ä/Ä 55ÌË (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 101.37
|
| ÑÏËÀÒ JUNIOR ÑÅÂÅÐ Ç/Ï Ä/Ä 55ÌË (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 101.51
|
| ÑÏËÀÒ JUNIOR ÞÃ Ç/Ï Ä/Ä 55ÌË (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 100.03
|
| ÑÏËÀÒ PROFESSIONAL DENTALLFLOSS ÇÓÁ. ÍÈÒÜ ÂÎËÎÊÍÀ ÑÅÐÅÁÐÀ 30Ì (ÔÑ-604) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ/PROFIMED S.R.L, ÈÒÀËÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ/PROFIMED S.R.L | | 83.44
|
| ÑÏËÀÒ PROFESSIONAL Ç/Ï ÀÊÒÈÂ 100ÌË (À-113) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 65.42
|
| ÑÏËÀÒ PROFESSIONAL Ç/Ï ÀÐÊÒÈÊÓÌ 100ÌË (ÀÊ-129) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 87.77
|
| ÑÏËÀÒ PROFESSIONAL Ç/Ï ÀÐÎÌÀÒÅÐÀÏÈß 100ÌË (ÀÐ-118) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 82.81
|
| ÑÏËÀÒ PROFESSIONAL Ç/Ï ÁÈÎÊÀËÜÖÈÉ 100ÌË (Á-114) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 60.61
|
| ÑÏËÀÒ PROFESSIONAL Ç/Ï ÁÈÎÊÀËÜÖÈÉ 40ÌË (Á-127) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 28.86
|
| ÑÏËÀÒ PROFESSIONAL Ç/Ï ÇÅËÅÍÛÉ ×ÀÉ 100ÌË (Ç-117) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 72.93
|
| ÑÏËÀÒ PROFESSIONAL Ç/Ï ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ 100ÌË (ËÒ-116) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 60.12
|
| ÑÏËÀÒ PROFESSIONAL Ç/Ï ËÈÊÂÓÌ-ÃÅËÜ 100ÌË (ËÃ-119) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 41.88
|
| ÑÏËÀÒ PROFESSIONAL Ç/Ï ÎÒÁÅËÈÂÀÍÈÅ ÏËÞÑ 100ÌË (Î-120) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 61.87
|
| ÑÏËÀÒ PROFESSIONAL Ç/Ï ÎÒÁÅËÈÂÀÍÈÅ ÏËÞÑ 40ÌË (Î-126) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 29.48
|
| ÑÏËÀÒ PROFESSIONAL Ç/Ï ÓËÜÒÐÀÊÎÌÏËÅÊÑ 40ÌË (Ó-128) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 29.04
|
| ÑÏËÀÒ SPECIAL Ç/Ï ÌÅ×ÒÀ 75ÌË (Ì-130) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 124.55
|
| ÑÏËÀÒ SPECIAL Ç/Ï ÌÎÐÑÊÈÅ ÌÈÍÅÐÀËÛ 75ÌË (S-107) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 94.67
|
| ÑÏËÀÒ SPECIAL Ç/Ï ÑÈÁÈÐÑÊÈÅ ßÃÎÄÛ 75ÌË (Ñß-132) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 126.96
|
| ÑÏËÀÒ SPECIAL Ç/Ï ×ÅÐÍÎÅ ÄÅÐÅÂÎ 75ÌË (×Ä-131) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 128.15
|
| ÑÏËÀÒ SPECIAL Ç/Ï ÝÊÑÒÐÀ ÎÒÁÅËÈÂÀÍÈÅ 75ÌË (ÝÎ-112) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 132.27
|
| ÑÏËÀÒ SPECIAL ÎÏÎËÀÑÊÈÂÀÒÅËÜ ÎÐÃÀÍÈÊ 340ÌË (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 81.64
|
| ÑÏËÀÒ Ç/Ï ×ÈËÈ 75ÌË (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 92.99
|
| ÑÏËÀÒ ÇÓÁÍÀß ÙÅÒÊÀ ÈÎÍÍÀß SPLAT ION SMART+ ÑÌÅÍ. ÍÀÑÀÄÊÀ (ÈÙ-606) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ßÏÎÍÈß) | ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ | | 314.87
|
| ÑÏÐÅÃÀËÜ ÑÏÐÅÉ 152Ã ¹1 (LABORATOIRES OMEGA PHARMA FRAN/S.C.A.T, ÔÐÀÍÖÈß) | LABORATOIRES OMEGA PHARMA FRAN/S.C.A.T | | 445.94
|
| ÑÏÐÅÉ ÏÈÒÀÍÈÅ ÄËß ÊÎÐÍÅÉ ÂÎËÎÑ Ñ ÖÈÍÊÎÌ È ÑÅËÅÍÎÌ 150ÌË ¹1 (ËÅÊÎÌÀÊÑ ÔÀÐÌÀ, ÐÎÑÑÈß) | ËÅÊÎÌÀÊÑ ÔÀÐÌÀ | | 117.98
|
| ÑÏÐÅÉ-ÁÀËÜÇÀÌ ÀÊÒÈÂÍÎÅ ÂÎÑÑÒÀÍÎÂËÅÍÈÅ ÂÎËÎÑ 150ÌË ¹1 (ËÅÊÎÌÀÊÑ ÔÀÐÌÀ, ÐÎÑÑÈß) | ËÅÊÎÌÀÊÑ ÔÀÐÌÀ | | 105.33
|
| ÑÏÐÅÉ-ÁÀËÜÇÀÌ ÂÈÒÀÌÈÍÛ ÐÎÑÒÀ ÂÎËÎÑ 150ÌË ¹1 (ËÅÊÎÌÀÊÑ ÔÀÐÌÀ, ÐÎÑÑÈß) | ËÅÊÎÌÀÊÑ ÔÀÐÌÀ | | 105.03
|
| ÑÏÐÈÍÖÎÂÊÀ ÏÂÕ Á ¹6 (Ñ ÄÂÓÌß ÍÀÊÎÍ.) (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß) | ÀËÜÔÀÏËÀÑÒÈÊ | | 20.8
|
| ÑÏÐÈÍÖÎÂÊÀ ÏÂÕ Á ¹9 (Ñ ÄÂÓÌß ÍÀÊÎÍ.) (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß) | ÀËÜÔÀÏËÀÑÒÈÊ | | 32.47
|
| ÑÏÐÈÍÖÎÂÊÀ ÐÅÇÈÍÎÂÀß À (ÌßÃÊ. ÍÀÊÎÍ.) ¹1 (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß) | ÀËÜÔÀÏËÀÑÒÈÊ | | 17.34
|
| ÑÏÐÈÍÖÎÂÊÀ ÐÅÇÈÍÎÂÀß À (ÌßÃÊ. ÍÀÊÎÍ.) ¹3 (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß) | ÀËÜÔÀÏËÀÑÒÈÊ | | 28.77
|
| ÑÐÅÄÑÒÂÎ SOS Ä/ÏÐÎÁË. ÊÎÆÈ ÌÃÍÎÂÅÍ. ÄÅÉÑÒÂÈß 15ÌË (ÝÂÈÍÀËÜ ÎÎÎ, ÐÎÑÑÈß) | ÝÂÈÍÀËÜ ÎÎÎ | | 120
|
| ÑÒÀÊÀÍ×ÈÊ ÌÅÐÍÛÉ ÔÝÑÒ Ä/ÄÎÇÈÐÎÂÀÍÍÎÃÎ ÏÐÈÅÌÀ ËÅÊÀÐÑÒ ¹1 (ÏÐÅÄÏÐÈßÒÈÅ ÔÝÑÒ, ÐÎÑÑÈß) | ÏÐÅÄÏÐÈßÒÈÅ ÔÝÑÒ | | 1.38
|
| ÑÒÈÇÀÌÅÒ ÌÀÇÜ 3% 35Ã ¹1 (ÐÅÒÈÍÎÈÄÛ, ÐÎÑÑÈß) | ÐÅÒÈÍÎÈÄÛ | | 67.68
|
| ÑÒÈÌÎË Ð-Ð Ä/ÂÍÓÒÐ.ÏÐÈÌ. 10ÌË ¹18 (BIOCODEX, ÔÐÀÍÖÈß) | BIOCODEX | | 273.55
|
| ÑÒÎÄÀËÜ ÑÈÐÎÏ 200ÌË ¹1 (BOIRON LABORATORIES, ÔÐÀÍÖÈß) | BOIRON LABORATORIES | | 143.55
|
| ÑÒÎÌÀÒÎÔÈÒ À Ð-Ð Ä/ÌÅÑÒÍ.ÏÐÈÌ. 25Ã ¹1 (PHYTOPHARM KLENKA, ÏÎËÜØÀ) | PHYTOPHARM KLENKA | | 112.21
|
| ÑÒÎÌÀÒÎÔÈÒ Ð-Ð Ä/ÌÅÑÒÍ.ÏÐÈÌ. 120ÌË ¹1 (PHYTOPHARM KLENKA, ÏÎËÜØÀ) | PHYTOPHARM KLENKA | | 150.24
|
| ÑÒÎÌÀÒÎÔÈÒ Ð-Ð Ä/ÌÅÑÒÍ.ÏÐÈÌ. 45ÌË ¹1 (PHYTOPHARM KLENKA, ÏÎËÜØÀ) | PHYTOPHARM KLENKA | | 93.03
|
| ÑÒÎÏÀÍÃÈÍ ÀÝÐÎÇÎËÜ 30ÌË ¹1 (IVAX-CR/GALENA, ×ÅÕÈß) | IVAX-CR/GALENA | | 118.68
|
| ÑÒÎÏÀÍÃÈÍ Ð-Ð Ä/ÌÅÑÒÍ.ÏÐÈÌ. 100ÌË ¹1 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 69.54
|
| ÑÒÎÏÀÍÃÈÍ Ð-Ð Ä/ÌÅÑÒÍ.ÏÐÈÌ. 100ÌË ¹1 (IVAX-CR/GALENA, ×ÅÕÈß) | IVAX-CR/GALENA | | 68.3
|
| ÑÒÎÏÀÐÒÐÎÇ 3,6Ã ÑÀØÅ ¹ 20 (SLAVIA FARM S.R.L., ÐÓÌÛÍÈß) | SLAVIA FARM S.R.L. | | 523.77
|
| ÑÒÎÏÒÓÑÑÈÍ ÊÀÏËÈ 10ÌË ¹1 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 45.32
|
| ÑÒÎÏÒÓÑÑÈÍ ÊÀÏËÈ 25ÌË ¹1 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 87.36
|
| ÑÒÎÏÒÓÑÑÈÍ ÊÀÏËÈ 50ÌË ¹1 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 143.88
|
| ÑÒÎÏÒÓÑÑÈÍ ÒÀÁ. ¹20 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 83.56
|
| ÑÒÎÏÒÓÑÑÈÍ-ÔÈÒÎ ÑÈÐÎÏ 100ÌË ¹1 (IVAX-CR, ×ÅÕÈß) | IVAX-CR | | 83.65
|
| ÑÒÐÀÒÒÅÐÀ ÊÀÏÑ. 18ÌÃ ¹7 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | ELI LILLY | | 906.27
|
| ÑÒÐÀÒÒÅÐÀ ÊÀÏÑ. 25ÌÃ ¹7 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | ELI LILLY | | 906.27
|
| ÑÒÐÀÒÒÅÐÀ ÊÀÏÑ. 25ÌÃ ¹7 (ELI LILLY, ÈÑÏÀÍÈß) | ELI LILLY | | 908.86
|
| ÑÒÐÀÒÒÅÐÀ ÊÀÏÑ. 40ÌÃ ¹7 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | ELI LILLY | | 906.27
|
| ÑÒÐÀÒÒÅÐÀ ÊÀÏÑ. 60ÌÃ ¹7 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | ELI LILLY | | 906.38
|
| ÑÒÐÅÇÀÌ ÊÀÏÑ. 50ÌÃ ¹24 (BIOCODEX, ÔÐÀÍÖÈß) | BIOCODEX | | 112.21
|
| ÑÒÐÅÏÑÈËÑ ÏËÞÑ ÑÏÐÅÉ 20ÌË ¹1 (BCM LTD, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | BCM LTD | | 255.05
|
| ÑÒÐÅÏÑÈËÑ ÏËÞÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹24 (RECKITT BENCKISER HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | RECKITT BENCKISER HEALTHCARE | | 137.18
|
| ÑÒÐÅÏÑÈËÑ Ñ ÂÈÒÀÌÈÍÎÌ Ñ ÒÀÁ. ¹36 (ÀÏÅËÜÑÈÍ) (RECKITT BENCKISER, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | RECKITT BENCKISER | | 119.84
|
| ÑÒÐÅÏÑÈËÑ Ñ ÂÈÒÀÌÈÍÎÌ Ñ ÒÀÁ. Ä/ÐÀÑÑ. ¹24 (ÀÏÅËÜÑÈÍ) (RECKITT BENCKISER/BOOTS HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | RECKITT BENCKISER/BOOTS HEALTHCARE | | 74.7
|
| ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹10 (ÌÅÄ-ËÈÌÎÍ) (RECKITT BENCKISER, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | RECKITT BENCKISER | | 72.36
|
| ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹24 (RECKITT BENCKISER HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | RECKITT BENCKISER HEALTHCARE | | 73.11
|
| ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹24 (ÌÅÄ-ËÈÌÎÍ) (RECKITT BENCKISER/BOOTS HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | RECKITT BENCKISER/BOOTS HEALTHCARE | | 82.28
|
| ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹24 (ÌÅÍÒ.-ÝÂÊÀË.) (RECKITT BENCKISER/BOOTS HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | RECKITT BENCKISER/BOOTS HEALTHCARE | | 98.97
|
| ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹24 (ÎÐÈÃÈÍ.) (RECKITT BENCKISER, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | RECKITT BENCKISER | | 75.25
|
| ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹36 (ÌÅÄ-ËÈÌÎÍ) (RECKITT BENCKISER/BOOTS HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | RECKITT BENCKISER/BOOTS HEALTHCARE | | 119.62
|
| ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. Á/ÑÀÕ. ¹24 (ËÈÌÎÍ) (RECKITT BENCKISER HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß) | RECKITT BENCKISER HEALTHCARE | | 111.64
|
| ÑÒÐÅÏÒÎÊÈÍÀÇÀ ËÈÎÔ.ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍ. 1500000 ÌÅ ¹1 (ÁÅËÌÅÄÏÐÅÏÀÐÀÒÛ ÐÓÏ, ÁÅËÀÐÓÑÜ) | ÁÅËÌÅÄÏÐÅÏÀÐÀÒÛ ÐÓÏ | | 11321.65
|
| ÑÒÐÅÏÒÎÌÈÖÈÍ ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍ. 1Ã ¹1 (ÑÈÍÒÅÇ ÀÊÎÌÏ, ÐÎÑÑÈß) | ÑÈÍÒÅÇ ÀÊÎÌÏ | | 6.08
|
| ÑÒÐÅÏÒÎÖÈÄ ËÈÍÈÌÅÍÒ 5% 30Ã ¹1 (ÍÈÆÔÀÐÌ, ÐÎÑÑÈß) | ÍÈÆÔÀÐÌ | | 30.36
|
| ÑÒÐÅÏÒÎÖÈÄ ÏÎÐ.Ä/ÍÀÐÓÆÍ.ÏÐÈÌ. 2Ã ¹1 (ËÞÌÈ, ÐÎÑÑÈß) | ËÞÌÈ | | 1.21
|
| ÑÒÐÅÏÒÎÖÈÄ ÏÎÐ.Ä/ÍÀÐÓÆÍ.ÏÐÈÌ. 2Ã ¹1 (ÌÎÑÊÎÂÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÌÎÑÊÎÂÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ | | 1.76
|
| ÑÒÐÅÏÒÎÖÈÄ ÏÎÐ.Ä/ÍÀÐÓÆÍ.ÏÐÈÌ. 2Ã ¹1 (ÒÓËÜÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ, ÐÎÑÑÈß) | ÒÓËÜÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ | | 2.19
|
| ÑÒÐÅÏÒÎÖÈÄ ÏÎÐ.Ä/ÍÀÐÓÆÍ.ÏÐÈÌ. 2Ã ¹1 (ÔÀÐÌÍÎÂÀÖÈß, ÐÎÑÑÈß) | ÔÀÐÌÍÎÂÀÖÈß | | 1.17
|
| ÑÒÐÅÏÒÎÖÈÄÎÂÀß ÌÀÇÜ ÌÀÇÜ 10% 25Ã ¹1 (ÁÈÎÑÈÍÒÅÇ, ÐÎÑÑÈß) | ÁÈÎÑÈÍÒÅÇ | | 26.12
|
| ÑÒÐÈÊÑ ÊÈÄÑ ÒÀÁ. ÆÅÂ. ¹30 (FERROSAN, ÄÀÍÈß) | FERROSAN | | 264.72
|
| ÑÒÐÈÊÑ ÒÀÁ. ¹30 (FERROSAN, ÄÀÍÈß) | FERROSAN | | 274
|
| ÑÒÐÈÊÑ ÔÎÐÒÅ ÒÀÁ. ¹30 (FERROSAN, ÄÀÍÈß) | FERROSAN | | 413.25
|
| ÑÒÐÎÔÀÍÒÈÍ Ê Ð-Ð Ä/ÈÍ. 0,025% 1ÌË ¹10 (ÃÀËÈ×ÔÀÐÌ ÀÎ, ÓÊÐÀÈÍÀ) | ÃÀËÈ×ÔÀÐÌ ÀÎ | | 16.68
|
| ÑÒÐÓÊÒÓÌ ÊÀÏÑ. 500ÌÃ ¹60 (PIERRE FABRE/ÑÎÒÅÊÑ, ÐÎÑÑÈß) | PIERRE FABRE/ÑÎÒÅÊÑ | | 1053.98
|
| ÑÒÓÃÅÐÎÍ ÒÀÁ. 25ÌÃ ¹50 (GEDEON RICHTER, ÂÅÍÃÐÈß) | GEDEON RICHTER | | 69.23
|
| ÑÓÄÍÎ ÏÎÄÊËÀÄÍÎÅ ÏÎËÈÌÅÐÍÎÅ ËÀÄÜß ¹1 (ÌÅÄÏÎËÈÌÅÐÒÎÐÃ, ÐÎÑÑÈß) | ÌÅÄÏÎËÈÌÅÐÒÎÐÃ | | 121.57
|
| ÑÓÄÍÎ ÏÎÄÊËÀÄÍÎÅ ÐÅÇÈÍÎÂÎÅ ¹1 (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß) | ÀËÜÔÀÏËÀÑÒÈÊ | | 267.77
|
| ÑÓÄÍÎ ÏÎÄÊËÀÄÍÎÅ ÐÅÇÈÍÎÂÎÅ ¹2 (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß) | ÀËÜÔÀÏËÀÑÒÈÊ | | 207.78
|
| ÑÓÄÍÎ ÏÎÄÊËÀÄÍÎÅ ÐÅÇÈÍÎÂÎÅ ¹3 (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß) | ÀËÜÔÀÏËÀÑÒÈÊ | | 230.55
|
| ÑÓÊÐÀÇÈÒ ÒÀÁ. ¹1200 (BISCOL CO. LTD, ÈÇÐÀÈËÜ) | BISCOL CO. LTD | | 85.59
|
| ÑÓËÜÃÈÍ ÒÀÁ. 500ÌÃ ¹10 (ÈÐÁÈÒÑÊÈÉ ÕÔÇ, ÐÎÑÑÈß) | ÈÐÁÈÒÑÊÈÉ ÕÔÇ | | 16.12
|
| ÑÓËÜÏÅÐÀÇÎÍ ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍ. 2Ã ¹1 (PFIZER, ÒÓÐÖÈß) | PFIZER | | 388.42
|
| ÑÓËÜÏÈÐÈÄ ÒÀÁ. 200ÌÃ ¹30 (ÎÐÃÀÍÈÊÀ, ÐÎÑÑÈß) | ÎÐÃÀÍÈÊÀ | | 46.2
|
| ÑÓËÜÏÈÐÈÄ ÒÀÁ. 50ÌÃ ¹30 (ÎÐÃÀÍÈÊÀ, ÐÎÑÑÈß) | ÎÐÃÀÍÈÊÀ | | 53.93
|
| ÑÓËÜÒÀÑÈÍ ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍ. 1,5Ã ¹1 (ÑÈÍÒÅÇ, ÐÎÑÑÈß) | ÑÈÍÒÅÇ | | 28.75
|
| ÑÓËÜÔÀÄÈÌÅÒÎÊÑÈÍ ÒÀÁ. 500ÌÃ ¹10 (ÁÈÎÑÈÍÒÅÇ, ÐÎÑÑÈß) | ÁÈÎÑÈÍÒÅÇ | | 12.04
|
| ÑÓËÜÔÀÄÈÌÅÒÎÊÑÈÍ ÒÀÁ. 500ÌÃ ¹10 (ÁÈÎÕÈÌÈÊ ÎÀÎ, ÐÎÑÑÈß) | ÁÈÎÕÈÌÈÊ ÎÀÎ | | 14.1
|
| ÑÓËÜÔÀÑÀËÀÇÈÍ ÒÀÁ. Ï/Î 500ÌÃ ¹50 (KRKA, ÑËÎÂÅÍÈß) | KRKA | | 236.33
|
| ÑÓËÜÔÀÑÀËÀÇÈÍ-ÅÍ ÒÀÁ. Ï/Î 500ÌÃ ¹50 (KRKA, ÑËÎÂÅÍÈß) | KRKA | | 243.04
|
| ÑÓËÜÔÀÖÈË-ÍÀÒÐÈÉ ÊÀÏËÈ ÃËÀÇÍÛÅ 20% 1,5ÌË ¹2 ÒÞÁ.-ÊÀÏ. (ÌÎÑÊÎÂÑÊÈÉ ÝÍÄÎÊÐÈÍÍÛÉ ÇÀÂÎÄ, ÐÎÑÑÈß) | ÌÎÑÊÎÂÑÊÈÉ ÝÍÄÎÊÐÈÍÍÛÉ ÇÀÂÎÄ | | 14.87
|
| ÑÓËÜÔÀÖÈË-ÍÀÒÐÈÉ ÊÀÏËÈ ÃËÀÇÍÛÅ 20% 10ÌË ¹1 ÔË.-ÊÀÏ. (ÑËÀÂßÍÑÊÀß ÀÏÒÅÊÀ, ÐÎÑÑÈß) | ÑËÀÂßÍÑÊÀß ÀÏÒÅÊÀ | | 8.48
|
| ÑÓËÜÔÀÖÈË-ÍÀÒÐÈÉ ÊÀÏËÈ ÃËÀÇÍÛÅ 20% 1ÌË ¹2 ÒÞÁ.-ÊÀÏ. (ÁÅËÌÅÄÏÐÅÏÀÐÀÒÛ ÐÓÏ, ÁÅËÀÐÓÑÜ) | ÁÅËÌÅÄÏÐÅÏÀÐÀÒÛ ÐÓÏ | | 16.96
|
| ÑÓËÜÔÀÖÈË-ÍÀÒÐÈÉ ÊÀÏËÈ ÃËÀÇÍÛÅ 20% 5ÌË ¹1 ÔË.-ÊÀÏ. (ÑÈÍÒÅÇ, ÐÎÑÑÈß) | ÑÈÍÒÅÇ | | 13.64
|
| ÑÓËÜÔÀÖÈË-ÍÀÒÐÈÉ ÊÀÏËÈ ÃËÀÇÍÛÅ 20% 5ÌË ¹1 ÔË.-ÊÀÏ. (ÑËÀÂßÍÑÊÀß ÀÏÒÅÊÀ, ÐÎÑÑÈß) | ÑËÀÂßÍÑÊÀß ÀÏÒÅÊÀ | | 7.17
|
| ÑÓËÜÔÀÖÈË-ÍÀÒÐÈÉ-ÄÈÀ ÊÀÏËÈ ÃËÀÇÍÛÅ 20% 5ÌË ¹1 (ÄÈÀÔÀÐÌ, ÐÎÑÑÈß) | ÄÈÀÔÀÐÌ | | 5.97
|
| ÑÓËÜÔÎÄÅÊÎÐÒÝÌ ÌÀÇÜ 25Ã ¹1 (ÍÈÆÔÀÐÌ, ÐÎÑÑÈß) | ÍÈÆÔÀÐÌ | | 25.65
|
| ÑÓËÜÔÎÊÀÌÔÎÊÀÈÍ Ð-Ð Ä/ÈÍ. 10% 2ÌË ¹10 (ÓÔÀÂÈÒÀ, ÐÎÑÑÈß) | ÓÔÀÂÈÒÀ | | 52.63
|
| ÑÓËÜÔÎÊÀÌÔÎÊÀÈÍ Ð-Ð Ä/ÈÍ. 10% 2ÌË ¹10 (ÔÀÐÌÑÒÀÍÄÀÐÒ-ÓÔÀÂÈÒÀ, ÐÎÑÑÈß) | ÔÀÐÌÑÒÀÍÄÀÐÒ-ÓÔÀÂÈÒÀ | | 54.66
|
| ÑÓÌÀÌÅÄ ËÈÎÔ.ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍÔ. 500ÌÃ ¹5 (PLIVA, ÕÎÐÂÀÒÈß) | PLIVA | | 1610.88
|
| ÑÓÌÀÌÅÄ ÏÎÐ.Ä/ÏÐÈÃ.ÑÓÑÏ.Ä/ÂÍÓÒÐ.ÏÐÈÌ. 100ÌÃ / 5ÌË 17Ã 23ÌË ¹1 (PLIVA, ÕÎÐÂÀÒÈß) | PLIVA | | 184.1
|
| ÑÓÌÀÌÅÄ ÒÀÁ. 125ÌÃ ¹6 (PLIVA, ÕÎÐÂÀÒÈß) | PLIVA | | 283.35
|
| ÑÓÌÀÌÅÄ ÒÀÁ. 500ÌÃ ¹3 (PLIVA, ÕÎÐÂÀÒÈß) | PLIVA | | 426.47
|
| ÑÓÌÀÌÅÄ ÔÎÐÒÅ ÏÎÐ.Ä/ÏÐÈÃ.ÑÓÑÏ.Ä/ÂÍÓÒÐ.ÏÐÈÌ. 200ÌÃ / 5ÌË 20ÌË ¹1 (PLIVA, ÕÎÐÂÀÒÈß) | PLIVA | | 307.25
|
| ÑÓÌÀÌÈÃÐÅÍ ÒÀÁ. Ï/Î 100ÌÃ ¹2 (POLPHARMA, ÏÎËÜØÀ) | POLPHARMA | | 266.61
|
| ÑÓÌÀÌÈÃÐÅÍ ÒÀÁ. Ï/Î 50ÌÃ ¹2 (POLPHARMA, ÏÎËÜØÀ) | POLPHARMA | | 156.47
|
| ÑÓÌÀÕ ÊÐÅÌ Ä/ÒÅËÀ 75ÌË (ÎÇÄÎÐÎÂÈÒÅËÜÍÛÅ ÁÈÎÒÅÕÍÎËÎÃÈÈ, ÐÎÑÑÈß) | ÎÇÄÎÐÎÂÈÒÅËÜÍÛÅ ÁÈÎÒÅÕÍÎËÎÃÈÈ | | 92.39
|
| ÑÓÏÅÐ×ÈÑÒÎÒÅË 1,2ÌË (ÀÑÏÅÐÀ, ÐÎÑÑÈß) | ÀÑÏÅÐÀ | | 12.17
|
| ÑÓÏÅÐ×ÈÑÒÎÒÅË 3,6ÌË (ÀÑÏÅÐÀ, ÐÎÑÑÈß) | ÀÑÏÅÐÀ | | 13.41
|
| ÑÓÏÐÀÄÈÍ ÒÀÁ. ¹30 (HOFFMANN LA ROCHE, ÔÐÀÍÖÈß) | HOFFMANN LA ROCHE | | 345.66
|
| ÑÓÏÐÀÄÈÍ ÒÀÁ. ØÈÏÓ×ÈÅ ¹10 (BAYER SANTE FAMILIALE, ÔÐÀÍÖÈß) | BAYER SANTE FAMILIALE | | 172.07
|
| ÑÓÏÐÀÊÑ ÃÐÀÍÓËÛ Ä/ÏÐÈÃ.ÑÓÑÏ.Ä/ÂÍÓÒÐ.ÏÐÈÌ. 100ÌÃ/5ÌË 30Ã ¹1 (HIKMA PHARMACEUTICALS/GEDEON RICHTER, ÈÎÐÄÀÍÈß/ÐÎÑÑÈß) | HIKMA PHARMACEUTICALS/GEDEON RICHTER | | 365.1
|
| ÑÓÏÐÀÊÑ ÊÀÏÑ. 400ÌÃ ¹6 (HIKMA PHARMACEUTICALS/GEDEON RICHTER, ÐÎÑÑÈß) | HIKMA PHARMACEUTICALS/GEDEON RICHTER | | 513.71
|
| ÑÓÏÐÀÑÒÈÍ Ð-Ð Ä/ÈÍ. 2% 1ÌË ¹5 (EGIS, ÂÅÍÃÐÈß) | EGIS | | 118.6
|
| ÑÓÏÐÀÑÒÈÍ ÒÀÁ. 25ÌÃ ¹20 (EGIS, ÂÅÍÃÐÈß) | EGIS | | 102.2
|
| ÑÓÏÐÅÍÀÌÈÍ ÒÀÁ. Ï/Î ¹20Õ2 (ÊËÈÍÈÊÀ ÈÍÑÒÈÒÓÒÀ ÃÅÐÎÍÒÎËÎÃÈÈ, ÐÎÑÑÈß) | ÊËÈÍÈÊÀ ÈÍÑÒÈÒÓÒÀ ÃÅÐÎÍÒÎËÎÃÈÈ | | 237.89
|
| ÑÓÏÐÈÌÀ-ÏËÞÑ ÌÀÇÜ 20Ã ¹1 (SHREYA LIFE, ÈÍÄÈß) | SHREYA LIFE | | 45.07
|
| ÑÓÑÒÀÍÎÍ-250 Ð-Ð ÄËß Â/Ì ÂÂÅÄ. 1ÌË ¹1 (ORGANON, ÍÈÄÅÐËÀÍÄÛ) | ORGANON | | 600.83
|
| ÑÓÑÒÀÑÒÈÍ ÁÀËÜÇÀÌ Ä/ÑÓÑÒÀÂΠ75ÌË (ÈÑÒÎ×ÍÈÊ ÄÎËÃÎËÅÒÈß, ÐÎÑÑÈß) | ÈÑÒÎ×ÍÈÊ ÄÎËÃÎËÅÒÈß | | 57.11
|
| ÑÓØÅÍÈÖÀ ÒÎÏßÍÀß 35à ¹1 (ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ, ÐÎÑÑÈß) | ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ | | 23.29
|
| ÑÛÂÎÐÎÒÊÀ ÌÓËÜÒÈÀÊÒ. INTENSIVE WAY 24 ÌÎÄÅËÈÐ. ÆÈÂÎÒ È ßÃÎÄ. 150ÌË (ËÈÍÄÀ ÏÊÔ ÎÎÎ, ÐÎÑÑÈß) | ËÈÍÄÀ ÏÊÔ ÎÎÎ | | 57.16
|
| ÑÛÂÎÐÎÒÊÀ Ñ ÝÊÑÒÐ. ÏËÀÖ. ÎÌÎËÀÆ. Ä/ÊÎÆÈ ÂÎÊÐÓÃ ÃËÀÇ 15ÌË (ÝÂÈÍÀËÜ ÎÎÎ, ÐÎÑÑÈß) | ÝÂÈÍÀËÜ ÎÎÎ | | 241.2
|
| ÑÛÂÎÐÎÒÊÀ Ñ ÝÊÑÒÐ. ÏËÀÖ. ÎÌÎËÀÆ. Ä/ÊÎÆÈ ËÈÖÀ 30ÌË (ÝÂÈÍÀËÜ ÎÎÎ, ÐÎÑÑÈß) | ÝÂÈÍÀËÜ ÎÎÎ | | 227.48
|
| ÑÛÂÎÐÎÒÊÀ Ñ ÝÊÑÒÐ. ÏËÀÖ. ÐÅÃÅÍ. È ÓÊÐÅÏË. Ä/ÂÎËÎÑ 150ÌË (ÝÂÈÍÀËÜ ÎÎÎ, ÐÎÑÑÈß) | ÝÂÈÍÀËÜ ÎÎÎ | | 135.96
|
| ÑÛÂÎÐÎÒÊÀ Ñ ÝÊÑÒÐ. ÏËÀÖ. ÐÅÃÅÍ. ÊÎÑÌÅÒÈ×. Ä/ÊÎÆÈ ÂÎÊÐÓà ÃËÀÇ 15ÌË (COSMEDIC LABORATORY, ÐÎÑÑÈß) | COSMEDIC LABORATORY | | 178.02
|
| ÑÛÂÎÐÎÒÊÀ Ñ ÝÊÑÒÐ. ÏËÀÖ. ÐÅÃÅÍ. ÓÍÈÂÅÐÑÀËÜÍÀß 50ÌË (COSMEDIC LABORATORY, ÐÎÑÑÈß) | COSMEDIC LABORATORY | | 160.25
|
